Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

SORT-OUT-3, 2010 - zotarolimus ES vs sirolimus ES

SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES

RESOLUTE, 2010 - zotarolimus ES vs everolimus ES

ISAR-DESIRE-2, 2010 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

COMPARE, 2009 - everolimus ES vs paclitaxel ES

ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES

ISAR TEST 3 (BP), 2009 - biodegradable-polymer sirolimus stent vs sirolimus ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG

PASEO, 2009 - drug ES vs bare-metal stent

ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol ES vs zotarolimus ES

ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

BARI 2D, 2009 - CABG or PCI vs medical treatment

GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent

SYNTAX, 2009 - paclitaxel ES vs CABG

ISAR-LEFT-MAIN, 2009 - sirolimus ES vs paclitaxel ES

ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES

ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol ES vs sirolimus ES

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus ES

Thiele, 2009 - sirolimus ES vs MIDCAB

Kim, 2008 - sirolimus ES vs paclitaxel ES

Costar II, 2008 - CoStar stent vs paclitaxel ES



See also:

  • All coronary artery disease clinical trials
  • All clinical trials of revascularization with drug eluting stent
  • All clinical trials of zotarolimus ES
    		•  

    ZEST (vs PES) study, 2009

    [NCT00418067]

    Treatments

    Studied treatment zotarolimus-eluting stents
    Control treatment paclitaxel-eluting stents
    Concomittant treatment aspirin and clopidogrel prior to the procedure. Aspirin was administered indefinitly and clopidogrel for at least 12 months. Heparin during PCI. Glycoprotein IIb/IIIa inhibitors at discretion

    Patients

    Patients Patients with coronary artery disease
    Exclusion criteria severe left ventricular dysfunction (left ventricular ejection fraction <25%); cardiogenic shock; renal insufficiency; liver dysfunction; left main stenosis; in-stent restenosis of a drug-eluting stent; poor life expectancy
    Baseline characteristics
    age 62y 
    diabetes (%) 30% 
    unstable angina (%) 55% 
    Female (%) 34% 
    bifurcated lesions 15% 
    ostial lesion 7% 
    multi vessels patients 47% 
    No of stent per lesions 1.2 
    No of lesions per patients 1.4 

    Method and design

    Randomized effectives 883 / 884 (studied vs. control)
    Blinding NA
    Follow-up duration 1 year
    Primary endpoint death, myocardial infarction, TLR
    Remarks

    Remarks / Comments



    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    6 / 883
         10 / 884
         0,60 [0,22;1,65]

    MI (fatal and non fatal)

    47 / 883
         62 / 884
         0,76 [0,53;1,10]

    target lesion revascularisation

    43 / 883
         66 / 884
         0,65 [0,45;0,95]

    Stent thrombosis (any, end of follow up)

    4 / 883
         6 / 884
         classic 0,67 [0,19;2,36]

    MACE

    89 / 883
         126 / 884
         0,71 [0,55;0,91]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 6 / 883 (0,7%) 10 / 884 (1,1%) 0,60 [0,22;1,65]    
    MI (fatal and non fatal) 47 / 883 (5,3%) 62 / 884 (7,0%) 0,76 [0,53;1,10]    
    MACE 89 / 883 (10,1%) 126 / 884 (14,3%) 0,71 [0,55;0,91]    
    Stent thrombosis (any, end of follow up) 4 / 883 (0,5%) 6 / 884 (0,7%) 0,67 [0,19;2,36]    
    target lesion revascularisation 43 / 883 (4,9%) 66 / 884 (7,5%) 0,65 [0,45;0,95]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 6,80‰ 1,13% -4,5‰
    MI (fatal and non fatal) 5,32% 7,01% -16,9‰
    MACE 10,08% 14,25% -41,7‰
    Stent thrombosis (any, end of follow up) 4,53‰ 6,79‰ -2,3‰
    target lesion revascularisation 4,87% 7,47% -26,0‰


    Reference(s)

    Trials register # NCT00418067
    • Seung-Jung Park . Comparison of Sirolimus and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial. ACC.09/i2, Orlando, FL, March 2009
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend